SELLAS Life Sciences (SLS) Stock Surges Over 200% After Phase 3 Leukemia Vaccine Win
In this news:
Key takeaways
- SELLAS Life Sciences stock jumped more than 200% after positive Phase 3 REGAL results for its leukemia vaccine GPS.
- GPS cut the risk of death by 41%; median survival was 24.0 months versus 14.7 months.
- SELLAS plans to meet the FDA and file for approval in the first half of 2027.
SELLAS Life Sciences (SLS) stock jumped more than 200% on Tuesday. The move came after the company reported positive Phase 3 results for its leukemia vaccine.
One early report put the gain at 240% at its peak. Buyers clearly wasted no time.
What the REGAL Trial Showed
The trial tested galinpepimut-S, known as GPS, in acute myeloid leukemia (AML). It met its main goal of overall survival.
Patients on GPS had a 41% lower risk of death than those on the best available treatment. The hazard ratio was 0.59, and the two-sided p-value was 0.035.
Median survival reached 24.0 months with GPS. The control group reached 14.7 months.
The analysis ran after 80 events, as the trial plan required. That timing was set in advance.
Everyone in the study had reached a second or later complete remission. They also could not have a stem cell transplant, or were not eligible for one.
GPS was given alone as maintenance therapy. Its safety profile matched earlier experience, with no new safety signals.
Most side effects were mild to moderate. The most common were reactions at the injection site.
What Comes Next for SELLAS
SELLAS plans to meet with the FDA to discuss a faster filing path. It is also preparing a Biologics License Application for the first half of 2027.
More detailed trial data is expected at an upcoming medical conference. The company has not been tied to a date in the reports.
A second leukemia drug is also moving along. Tambiciclib, or SLS009, is a CDK9 inhibitor in Phase 2 testing.
Forty patients have enrolled in its study of newly diagnosed AML. Early findings are expected before year-end.
More SLS009 data is headed to the American Society of Hematology meeting in December. Earlier work in relapsed or resistant AML showed response rates of 54% in monocytic AML and 57% in patients with TP53 mutations.
SELLAS ended September with $134.7 million in cash and equivalents. Its third-quarter net loss was $10.1 million, up from $6.8 million a year earlier.
Maxim analyst Jason McCarthy rates the stock a Buy with a $30 price target. He models GPS revenue starting in 2027 and SLS009 in first-line AML in 2029.
Tuesday’s rally has pushed the stock much closer to that target.
Source: blockonomi.com
Share the article:
Trending News & Crypto World
Latest Money News
Top Trending Cryptocurrencies on The Market
Current Price
$99.760
Market Cap
$263.3M 3.09%
24h Volume
$581.4K
Supplies
3.0M / 3.0M
Current Price
$0.03847
Market Cap
$259.0M -1.98%
24h Volume
$21.7M
Supplies
10.0B / ∞
Current Price
$1.028
Market Cap
$256.1M 0.51%
24h Volume
-
Supplies
249.1M / ∞
Current Price
$0.03231
Market Cap
$253.2M -0.71%
24h Volume
$44.5M
Supplies
10.2B / ∞
Current Price
$1.440
Market Cap
$250.2M 2.35%
24h Volume
$39.1M
Supplies
281.5M / ∞
Current Price
$0.9999
Market Cap
$249.9M -0.07%
24h Volume
$131.6M
Supplies
5.0B / ∞
Current Price
$0.00004505
Market Cap
$248.8M 15.06%
24h Volume
$40.3M
Supplies
6.4T / ∞
Current Price
$0.9419
Market Cap
$235.5M -6.64%
24h Volume
$3.9M
Supplies
1000.0M / 1.0B
Current Price
$15.510
Market Cap
$231.2M -0.14%
24h Volume
$208.9K
Supplies
19.8M / ∞
Current Price
$0.2091
Market Cap
$230.4M 0.11%
24h Volume
$4.4M
Supplies
1.1B / ∞
Current Price
$1.000
Market Cap
$227.5M 0%
24h Volume
-
Supplies
227.5M / 400.0M
Current Price
$0.04761
Market Cap
$226.7M 2.43%
24h Volume
$28.8M
Supplies
10.0B / ∞